-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The eighth batch of collection of collection affects the nerves of the industry, as the key object of collection, the whole body with antibacterial drugs has 16 varieties to meet the conditions of 4, in 2021 China's public medical institutions terminal sales scale totaled more than 31 billion yuan, of which 9 varieties of annual sales of more than 1 billion, 5 varieties of competitive enterprises more than 8, North China Pharmaceutical, Kelun, Beite, Qilu and other varieties in the list
.
.
120 billion antibacterial drug market! Cephalosporins account for nearly half of the country
In recent years, a series of policies such as restricted transmission, limited antibody and collection and collection have affected
the market for systemic antibacterial drugs.
According to data from the intranet, in 2021, the sales scale of terminal antibacterial drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 120 billion yuan, an increase of 2.
55%
year-on-year.
the market for systemic antibacterial drugs.
According to data from the intranet, in 2021, the sales scale of terminal antibacterial drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 120 billion yuan, an increase of 2.
55%
year-on-year.
Sales of terminal systemic antibacterial drugs in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
From the perspective of subdivision categories, the top 5 sales of antibacterial drugs are cephalosporins, penicillins, other antibacterial drugs, carbapenems, and quinolone antibacterial drugs
.
As the focus of collection, the sales scale of cephalosporin antibacterial drugs has continued to shrink in recent years, but it is still in a leading position in the market, with a market share of 46.
77%
in 2021.
Penicillin-based antimicrobials ranked second in the market, with sales in 2021 up 12.
15%
year-on-year.
Due to the successive inclusion of the main varieties in the collection, the sales of quinolone antibacterial drugs in 2021 fell by 18.
26%
year-on-year.
.
As the focus of collection, the sales scale of cephalosporin antibacterial drugs has continued to shrink in recent years, but it is still in a leading position in the market, with a market share of 46.
77%
in 2021.
Penicillin-based antimicrobials ranked second in the market, with sales in 2021 up 12.
15%
year-on-year.
Due to the successive inclusion of the main varieties in the collection, the sales of quinolone antibacterial drugs in 2021 fell by 18.
26%
year-on-year.
From the perspective of manufacturer pattern, the market leader of cephalosporin antibacterial drugs is Pfizer, accounting for 10.
76% of the market share; The leading enterprises in the penicillin antibacterial market are North China Pharmaceutical and Ruiyang Pharmaceutical, with a market share of more than 12%; The market for carbapenem antimicrobials is dominated by Sumitomo and Merck of Japan, with market shares of 24.
88% and 23.
35% respectively; The top 3 enterprises in the market sales of quinolone antibacterial drugs are Zhejiang Pharmaceutical, Yangzijiang Pharmaceutical, and the first three totals
.
76% of the market share; The leading enterprises in the penicillin antibacterial market are North China Pharmaceutical and Ruiyang Pharmaceutical, with a market share of more than 12%; The market for carbapenem antimicrobials is dominated by Sumitomo and Merck of Japan, with market shares of 24.
88% and 23.
35% respectively; The top 3 enterprises in the market sales of quinolone antibacterial drugs are Zhejiang Pharmaceutical, Yangzijiang Pharmaceutical, and the first three totals
.
36 antibacterial drugs have been collected, and 4 varieties of more than 1 billion varieties have been "waist chopped"
In the six batches of chemical drug collection carried out by the state, 1, 6, 7, 3, 8 and 11 varieties of systemic antibacterial drugs were included in the collection, with a total of 36 varieties
.
Among them, cephalosporin antibacterial drugs bore the brunt of it, and a total of 16 varieties were included in the collection; Followed by macrolide antibacterial drugs and quinolone antibacterial drugs, 6 varieties were included in the collection
.
.
Among them, cephalosporin antibacterial drugs bore the brunt of it, and a total of 16 varieties were included in the collection; Followed by macrolide antibacterial drugs and quinolone antibacterial drugs, 6 varieties were included in the collection
.
Cefuroxime oral regular-release dosage form was once a large 2 billion yuan variety, and it was the only antibacterial drug
that was included in the first batch of collections.
The 4+7 pilot was implemented in March 2019, and the alliance expansion was implemented
in December of that year.
As the first antibacterial drug to be included in the collection, the sales scale of cefuroxime oral regular-release dosage forms continued to decline in the three years since it entered the collection, and the terminal sales of public medical institutions in China in 2019-2021 fell by 8.
08%, 54.
13% and 3.
44% respectively year-on-year, and the sales of the product exceeded 800 million yuan
in 2021.
that was included in the first batch of collections.
The 4+7 pilot was implemented in March 2019, and the alliance expansion was implemented
in December of that year.
As the first antibacterial drug to be included in the collection, the sales scale of cefuroxime oral regular-release dosage forms continued to decline in the three years since it entered the collection, and the terminal sales of public medical institutions in China in 2019-2021 fell by 8.
08%, 54.
13% and 3.
44% respectively year-on-year, and the sales of the product exceeded 800 million yuan
in 2021.
Sales of terminal cefuroxime oral regular-release dosage forms in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The second batch of systemic antibacterial drugs included in the collection includes 6, including amoxicillin oral regular-release dosage form, azithromycin oral regular-release dosage form, clindamycin oral regular-release dosage form, moxifloxacin oral regular-release dosage form, cefoxin oral regular-release dosage form, cefladine oral normal-release dosage form, and the implementation time is May
2020.
Among them, amoxicillin oral regular-release dosage forms and azithromycin oral regular-release dosage forms were included in the pre-harvest sales scale of more than 1.
5 billion yuan
.
2020.
Among them, amoxicillin oral regular-release dosage forms and azithromycin oral regular-release dosage forms were included in the pre-harvest sales scale of more than 1.
5 billion yuan
.
The terminal sales scale of amoxicillin oral regular-release dosage forms in China's public medical institutions exceeded 1.
6 billion yuan in 2019, and fell by 39.
28% and 21.
81% year-on-year from 2020 to 2021, respectively, and the sales scale in 2021 was less than 800 million yuan
.
Among them, amoxicillin capsules in 2021 sales TOP3 manufacturers for CSPC Zhongnuo Pharmaceutical, Lukang Pharmaceutical, North China Pharmaceutical, are the third batch of collection of this variety of winning enterprises, and the market share is a step forward compared with the collection
and mining.
6 billion yuan in 2019, and fell by 39.
28% and 21.
81% year-on-year from 2020 to 2021, respectively, and the sales scale in 2021 was less than 800 million yuan
.
Among them, amoxicillin capsules in 2021 sales TOP3 manufacturers for CSPC Zhongnuo Pharmaceutical, Lukang Pharmaceutical, North China Pharmaceutical, are the third batch of collection of this variety of winning enterprises, and the market share is a step forward compared with the collection
and mining.
Sales of terminal amoxicillin oral regular-release dosage forms in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The terminal sales scale of azithromycin oral regular-release dosage forms in China's public medical institutions exceeded 1.
5 billion yuan in 2019, and in 2020 and 2021, respectively, it fell by 64.
30% and 47.
53% year-on-year, and the sales scale in 2021 was less than 300 million yuan
.
The selected varieties of the third batch of oral regular-release dosage forms of azithromycin include azithromycin tablets and azithromycin capsules
.
Specific to the product of azithromycin tablets, the market share of the original manufacturer Pfizer fell from 80.
33% in 2018 to 38.
92%
in 2021.
5 billion yuan in 2019, and in 2020 and 2021, respectively, it fell by 64.
30% and 47.
53% year-on-year, and the sales scale in 2021 was less than 300 million yuan
.
The selected varieties of the third batch of oral regular-release dosage forms of azithromycin include azithromycin tablets and azithromycin capsules
.
Specific to the product of azithromycin tablets, the market share of the original manufacturer Pfizer fell from 80.
33% in 2018 to 38.
92%
in 2021.
Sales of terminal azithromycin oral regular-release dosage forms in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
Moxifloxacin sodium chloride injection is the third batch of collected varieties and the first antibacterial drug injection to be included
in the collection.
The third batch of collection and collection execution time is November 2020, moxifloxacin sodium chloride injection in China's public medical institutions terminal sales scale of more than 4 billion yuan in 2019, an increase of 22.
88% year-on-year, 2020, 2021 respectively fell by 13.
23%, 46.
64%, 2021 sales scale of nearly 1.
9 billion yuan
.
in the collection.
The third batch of collection and collection execution time is November 2020, moxifloxacin sodium chloride injection in China's public medical institutions terminal sales scale of more than 4 billion yuan in 2019, an increase of 22.
88% year-on-year, 2020, 2021 respectively fell by 13.
23%, 46.
64%, 2021 sales scale of nearly 1.
9 billion yuan
.
Sales of terminal moxifloxacin sodium chloride injection in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The only selected enterprises in the national selection of moxifloxacin sodium chloride injection are Hongri Pharmaceutical and Hainan Aike Pharmaceutical, and the products of both companies were approved for listing in 2020, with zero
market share.
In 2021, the sales of Moxifloxacin sodium chloride injections of Hainan Aike Pharmaceutical and Hongri Pharmaceutical, the terminals of China's public medical institutions, increased by 602.
37% and 302.
11% respectively year-on-year, and the market ranked third and fifth
, respectively.
market share.
In 2021, the sales of Moxifloxacin sodium chloride injections of Hainan Aike Pharmaceutical and Hongri Pharmaceutical, the terminals of China's public medical institutions, increased by 602.
37% and 302.
11% respectively year-on-year, and the market ranked third and fifth
, respectively.
16 varieties of 31 billion market changes, 9 annual sales of more than 1 billion
In addition to the varieties that have been included in the national collection, there are currently 16 varieties of systemic antibacterial drugs that meet the national collection conditions (4 have been evaluated/ 3 have been evaluated + original research).
Among them, there are as many as 12 injections, 3 oral regular-release dosage forms, and 1 granule
.
Among them, there are as many as 12 injections, 3 oral regular-release dosage forms, and 1 granule
.
Systemic antibacterial drugs that meet the conditions of 4 households
According to data from the intranet, the total sales scale of 16 varieties in China's public medical institutions will exceed 31 billion yuan
in 2021.
Among them, the sales of 9 varieties exceeded 1 billion yuan, the sales of piperacillintazobactam injection exceeded 8.
3 billion yuan, and the sales of cefoperazone sulbactam injection exceeded 7 billion yuan; Sales of three varieties, including compound sulfamethoxazole oral regular-release dosage form, cefdinib granules, and sitaxacin oral regular-release dosage form, are less than 100 million yuan
.
in 2021.
Among them, the sales of 9 varieties exceeded 1 billion yuan, the sales of piperacillintazobactam injection exceeded 8.
3 billion yuan, and the sales of cefoperazone sulbactam injection exceeded 7 billion yuan; Sales of three varieties, including compound sulfamethoxazole oral regular-release dosage form, cefdinib granules, and sitaxacin oral regular-release dosage form, are less than 100 million yuan
.
It is worth mentioning that the compound sulfamethoxazole oral regular-release dosage form is the seventh batch of collection and flow standard varieties, which have been evaluated by 8 companies, and the last company has been evaluated on March 30, 2022
.
Due to the small scale of this variety, if it is included in the next batch of collection, it is expected that the bidding enthusiasm of related enterprises will not be high
.
.
Due to the small scale of this variety, if it is included in the next batch of collection, it is expected that the bidding enthusiasm of related enterprises will not be high
.
From the perspective of competition pattern, there are as many as 9 competitive enterprises for cefoxitin injection, 8 competitive enterprises in four varieties, such as ornidazole injection, compound sulfamethoxazole oral regular-release dosage form, cefotaxime injection, cefoperazone sulbactam injection, etc.
, and the competition is fierce; There are 4 competitive enterprises in four varieties, such as ceftiam injection, cefdinib granules, ciprofloxacin injection, and sitafloxacin oral regular-release dosage form, and the competition pattern is good
.
, and the competition is fierce; There are 4 competitive enterprises in four varieties, such as ceftiam injection, cefdinib granules, ciprofloxacin injection, and sitafloxacin oral regular-release dosage form, and the competition pattern is good
.
In addition, although metronidazole injection has as many as 11 rated companies, because 6 companies belong to the Coron Group, the competition pattern of this variety is 6+1
.
.
From the perspective of evaluated enterprises, the number of overrated varieties involved in North China Pharmaceutical is as high as 6, and 5 enterprises such as Kelun Pharmaceutical, Beite Pharmaceutical, Qilu Pharmaceutical, Xinlitai and China Resources Pharmaceutical have 3 varieties listed
.
.
Pictures of 16 systemic antibacterial companies eligible
Source: Intranet database
Note: The statistical scope of "China's Public Medical Institutions Terminal Competition Pattern" is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
based on the average retail price of the product at the terminal.
The eighth batch of collection of collection affects the nerves of the industry, as the key object of collection, the whole body with antibacterial drugs has 16 varieties to meet the conditions of 4, in 2021 China's public medical institutions terminal sales scale totaled more than 31 billion yuan, of which 9 varieties of annual sales of more than 1 billion, 5 varieties of competitive enterprises more than 8, North China Pharmaceutical, Kelun, Beite, Qilu and other varieties in the list
.
.
120 billion antibacterial drug market! Cephalosporins account for nearly half of the country
120 billion antibacterial drug market! Cephalosporins account for nearly half of the country In recent years, a series of policies such as restricted transmission, limited antibody and collection and collection have affected
the market for systemic antibacterial drugs.
According to data from the intranet, in 2021, the sales scale of terminal antibacterial drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 120 billion yuan, an increase of 2.
55%
year-on-year.
the market for systemic antibacterial drugs.
According to data from the intranet, in 2021, the sales scale of terminal antibacterial drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) exceeded 120 billion yuan, an increase of 2.
55%
year-on-year.
Sales of terminal systemic antibacterial drugs in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
From the perspective of subdivision categories, the top 5 sales of antibacterial drugs are cephalosporins, penicillins, other antibacterial drugs, carbapenems, and quinolone antibacterial drugs
.
As the focus of collection, the sales scale of cephalosporin antibacterial drugs has continued to shrink in recent years, but it is still in a leading position in the market, with a market share of 46.
77%
in 2021.
Penicillin-based antimicrobials ranked second in the market, with sales in 2021 up 12.
15%
year-on-year.
Due to the successive inclusion of the main varieties in the collection, the sales of quinolone antibacterial drugs in 2021 fell by 18.
26%
year-on-year.
.
As the focus of collection, the sales scale of cephalosporin antibacterial drugs has continued to shrink in recent years, but it is still in a leading position in the market, with a market share of 46.
77%
in 2021.
Penicillin-based antimicrobials ranked second in the market, with sales in 2021 up 12.
15%
year-on-year.
Due to the successive inclusion of the main varieties in the collection, the sales of quinolone antibacterial drugs in 2021 fell by 18.
26%
year-on-year.
From the perspective of manufacturer pattern, the market leader of cephalosporin antibacterial drugs is Pfizer, accounting for 10.
76% of the market share; The leading enterprises in the penicillin antibacterial market are North China Pharmaceutical and Ruiyang Pharmaceutical, with a market share of more than 12%; The market for carbapenem antimicrobials is dominated by Sumitomo and Merck of Japan, with market shares of 24.
88% and 23.
35% respectively; The top 3 enterprises in the market sales of quinolone antibacterial drugs are Zhejiang Pharmaceutical, Yangzijiang Pharmaceutical, and the first three totals
.
76% of the market share; The leading enterprises in the penicillin antibacterial market are North China Pharmaceutical and Ruiyang Pharmaceutical, with a market share of more than 12%; The market for carbapenem antimicrobials is dominated by Sumitomo and Merck of Japan, with market shares of 24.
88% and 23.
35% respectively; The top 3 enterprises in the market sales of quinolone antibacterial drugs are Zhejiang Pharmaceutical, Yangzijiang Pharmaceutical, and the first three totals
.
36 antibacterial drugs have been collected, and 4 varieties of more than 1 billion varieties have been "waist chopped"
36 antibacterial drugs have been collected, and 4 varieties of more than 1 billion varieties have been "waist chopped" In the six batches of chemical drug collection carried out by the state, 1, 6, 7, 3, 8 and 11 varieties of systemic antibacterial drugs were included in the collection, with a total of 36 varieties
.
Among them, cephalosporin antibacterial drugs bore the brunt of it, and a total of 16 varieties were included in the collection; Followed by macrolide antibacterial drugs and quinolone antibacterial drugs, 6 varieties were included in the collection
.
.
Among them, cephalosporin antibacterial drugs bore the brunt of it, and a total of 16 varieties were included in the collection; Followed by macrolide antibacterial drugs and quinolone antibacterial drugs, 6 varieties were included in the collection
.
Cefuroxime oral regular-release dosage form was once a large 2 billion yuan variety, and it was the only antibacterial drug
that was included in the first batch of collections.
The 4+7 pilot was implemented in March 2019, and the alliance expansion was implemented
in December of that year.
As the first antibacterial drug to be included in the collection, the sales scale of cefuroxime oral regular-release dosage forms continued to decline in the three years since it entered the collection, and the terminal sales of public medical institutions in China in 2019-2021 fell by 8.
08%, 54.
13% and 3.
44% respectively year-on-year, and the sales of the product exceeded 800 million yuan
in 2021.
that was included in the first batch of collections.
The 4+7 pilot was implemented in March 2019, and the alliance expansion was implemented
in December of that year.
As the first antibacterial drug to be included in the collection, the sales scale of cefuroxime oral regular-release dosage forms continued to decline in the three years since it entered the collection, and the terminal sales of public medical institutions in China in 2019-2021 fell by 8.
08%, 54.
13% and 3.
44% respectively year-on-year, and the sales of the product exceeded 800 million yuan
in 2021.
Sales of terminal cefuroxime oral regular-release dosage forms in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The second batch of systemic antibacterial drugs included in the collection includes 6, including amoxicillin oral regular-release dosage form, azithromycin oral regular-release dosage form, clindamycin oral regular-release dosage form, moxifloxacin oral regular-release dosage form, cefoxin oral regular-release dosage form, cefladine oral normal-release dosage form, and the implementation time is May
2020.
Among them, amoxicillin oral regular-release dosage forms and azithromycin oral regular-release dosage forms were included in the pre-harvest sales scale of more than 1.
5 billion yuan
.
2020.
Among them, amoxicillin oral regular-release dosage forms and azithromycin oral regular-release dosage forms were included in the pre-harvest sales scale of more than 1.
5 billion yuan
.
The terminal sales scale of amoxicillin oral regular-release dosage forms in China's public medical institutions exceeded 1.
6 billion yuan in 2019, and fell by 39.
28% and 21.
81% year-on-year from 2020 to 2021, respectively, and the sales scale in 2021 was less than 800 million yuan
.
Among them, amoxicillin capsules in 2021 sales TOP3 manufacturers for CSPC Zhongnuo Pharmaceutical, Lukang Pharmaceutical, North China Pharmaceutical, are the third batch of collection of this variety of winning enterprises, and the market share is a step forward compared with the collection
and mining.
Pharmaceutical enterprises6 billion yuan in 2019, and fell by 39.
28% and 21.
81% year-on-year from 2020 to 2021, respectively, and the sales scale in 2021 was less than 800 million yuan
.
Among them, amoxicillin capsules in 2021 sales TOP3 manufacturers for CSPC Zhongnuo Pharmaceutical, Lukang Pharmaceutical, North China Pharmaceutical, are the third batch of collection of this variety of winning enterprises, and the market share is a step forward compared with the collection
and mining.
Sales of terminal amoxicillin oral regular-release dosage forms in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The terminal sales scale of azithromycin oral regular-release dosage forms in China's public medical institutions exceeded 1.
5 billion yuan in 2019, and in 2020 and 2021, respectively, it fell by 64.
30% and 47.
53% year-on-year, and the sales scale in 2021 was less than 300 million yuan
.
The selected varieties of the third batch of oral regular-release dosage forms of azithromycin include azithromycin tablets and azithromycin capsules
.
Specific to the product of azithromycin tablets, the market share of the original manufacturer Pfizer fell from 80.
33% in 2018 to 38.
92%
in 2021.
5 billion yuan in 2019, and in 2020 and 2021, respectively, it fell by 64.
30% and 47.
53% year-on-year, and the sales scale in 2021 was less than 300 million yuan
.
The selected varieties of the third batch of oral regular-release dosage forms of azithromycin include azithromycin tablets and azithromycin capsules
.
Specific to the product of azithromycin tablets, the market share of the original manufacturer Pfizer fell from 80.
33% in 2018 to 38.
92%
in 2021.
Sales of terminal azithromycin oral regular-release dosage forms in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
Moxifloxacin sodium chloride injection is the third batch of collected varieties and the first antibacterial drug injection to be included
in the collection.
The third batch of collection and collection execution time is November 2020, moxifloxacin sodium chloride injection in China's public medical institutions terminal sales scale of more than 4 billion yuan in 2019, an increase of 22.
88% year-on-year, 2020, 2021 respectively fell by 13.
23%, 46.
64%, 2021 sales scale of nearly 1.
9 billion yuan
.
in the collection.
The third batch of collection and collection execution time is November 2020, moxifloxacin sodium chloride injection in China's public medical institutions terminal sales scale of more than 4 billion yuan in 2019, an increase of 22.
88% year-on-year, 2020, 2021 respectively fell by 13.
23%, 46.
64%, 2021 sales scale of nearly 1.
9 billion yuan
.
Sales of terminal moxifloxacin sodium chloride injection in public medical institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
The only selected enterprises in the national selection of moxifloxacin sodium chloride injection are Hongri Pharmaceutical and Hainan Aike Pharmaceutical, and the products of both companies were approved for listing in 2020, with zero
market share.
In 2021, the sales of Moxifloxacin sodium chloride injections of Hainan Aike Pharmaceutical and Hongri Pharmaceutical, the terminals of China's public medical institutions, increased by 602.
37% and 302.
11% respectively year-on-year, and the market ranked third and fifth
, respectively.
market share.
In 2021, the sales of Moxifloxacin sodium chloride injections of Hainan Aike Pharmaceutical and Hongri Pharmaceutical, the terminals of China's public medical institutions, increased by 602.
37% and 302.
11% respectively year-on-year, and the market ranked third and fifth
, respectively.
16 varieties of 310 billion market changes, 9 annual sales of more than 10 billion
16 varieties of 310 billion market changes, 9 annual sales of more than 10 billion In addition to the varieties that have been included in the national collection, there are currently 16 varieties of systemic antibacterial drugs that meet the national collection conditions (4 have been evaluated/ 3 have been evaluated + original research).
Among them, there are as many as 12 injections, 3 oral regular-release dosage forms, and 1 granule
.
Among them, there are as many as 12 injections, 3 oral regular-release dosage forms, and 1 granule
.
Systemic antibacterial drugs that meet the conditions of 4 households
According to data from the intranet, the total sales scale of 16 varieties in China's public medical institutions will exceed 31 billion yuan
in 2021.
Among them, the sales of 9 varieties exceeded 1 billion yuan, the sales of piperacillintazobactam injection exceeded 8.
3 billion yuan, and the sales of cefoperazone sulbactam injection exceeded 7 billion yuan; Sales of three varieties, including compound sulfamethoxazole oral regular-release dosage form, cefdinib granules, and sitaxacin oral regular-release dosage form, are less than 100 million yuan
.
in 2021.
Among them, the sales of 9 varieties exceeded 1 billion yuan, the sales of piperacillintazobactam injection exceeded 8.
3 billion yuan, and the sales of cefoperazone sulbactam injection exceeded 7 billion yuan; Sales of three varieties, including compound sulfamethoxazole oral regular-release dosage form, cefdinib granules, and sitaxacin oral regular-release dosage form, are less than 100 million yuan
.
It is worth mentioning that the compound sulfamethoxazole oral regular-release dosage form is the seventh batch of collection and flow standard varieties, which have been evaluated by 8 companies, and the last company has been evaluated on March 30, 2022
.
Due to the small scale of this variety, if it is included in the next batch of collection, it is expected that the bidding enthusiasm of related enterprises will not be high
.
.
Due to the small scale of this variety, if it is included in the next batch of collection, it is expected that the bidding enthusiasm of related enterprises will not be high
.
From the perspective of competition pattern, there are as many as 9 competitive enterprises for cefoxitin injection, 8 competitive enterprises in four varieties, such as ornidazole injection, compound sulfamethoxazole oral regular-release dosage form, cefotaxime injection, cefoperazone sulbactam injection, etc.
, and the competition is fierce; There are 4 competitive enterprises in four varieties, such as ceftiam injection, cefdinib granules, ciprofloxacin injection, and sitafloxacin oral regular-release dosage form, and the competition pattern is good
.
, and the competition is fierce; There are 4 competitive enterprises in four varieties, such as ceftiam injection, cefdinib granules, ciprofloxacin injection, and sitafloxacin oral regular-release dosage form, and the competition pattern is good
.
In addition, although metronidazole injection has as many as 11 rated companies, because 6 companies belong to the Coron Group, the competition pattern of this variety is 6+1
.
.
From the perspective of evaluated enterprises, the number of overrated varieties involved in North China Pharmaceutical is as high as 6, and 5 enterprises such as Kelun Pharmaceutical, Beite Pharmaceutical, Qilu Pharmaceutical, Xinlitai and China Resources Pharmaceutical have 3 varieties listed
.
.
Pictures of 16 systemic antibacterial companies eligible
Source: Intranet database
Note: The statistical scope of "China's Public Medical Institutions Terminal Competition Pattern" is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Hospital Hospital based on the average retail price of the product at the terminal.
